Dave Ricks, CEO of Eli Lilly, on GLP-1s and the business of pharma
2:06:41
YouTubeStripe
Dave Ricks, CEO of Eli Lilly, on GLP-1s and the business of pharma
Dave Ricks, the CEO of Eli Lilly, the world's most valuable pharmaceutical company, sits down with John and Patrick to discuss the complex business of drug development. Dave explains the true origin story of GLP-1s (from Gila monster saliva), why their potential goes far beyond weight loss to addiction and inflammation, and how "self-pay" has ...
31.3K views1 week ago
Pharmaceutical Development and Technology Impact Factor
Inside the Pharmaceutical Manufacturing Process
1:14
Inside the Pharmaceutical Manufacturing Process
YouTubeCarolina Pharma
6.3K viewsMay 18, 2023
From Molecule to Medicine: The Drug Development Process
0:43
From Molecule to Medicine: The Drug Development Process
YouTubeDelli Docs
4.7K views1 month ago
How AI Is Transforming The Pharmaceutical Industry
1:05
How AI Is Transforming The Pharmaceutical Industry
YouTubeNeuron Expert
30 views8 months ago
Top videos
AI-Driven Pharma: Turning Data Into Discovery | Pharma Talks
35:17
AI-Driven Pharma: Turning Data Into Discovery | Pharma Talks
YouTubeViseven
2.5K views6 days ago
Fosun Biz-Insights: Eight Years at the CIIE, the Making of Fosun’s Open Innovation Journey
7:42
Fosun Biz-Insights: Eight Years at the CIIE, the Making of Fosun’s Open Innovation Journey
YouTubeFosun
13.3K views4 days ago
A newly-released video from eXoZymes (Nasdaq: EXOZ) offers a compelling look at how the company is using AI-driven enzyme engineering to expand the potential of NCT. eXoZymes is a B2i Digital Featured Company. See the full profile at https://b2idigital.com/exozymes-1. As Michael Heltzen, CEO of eXoZymes, explains in the interview, GLP-1 drugs reduce appetite while NCT supports metabolism in a different way. He notes that NCT has been part of the human diet for a long time, although meaningful do
0:09
A newly-released video from eXoZymes (Nasdaq: EXOZ) offers a compelling look at how the company is using AI-driven enzyme engineering to expand the potential of NCT. eXoZymes is a B2i Digital Featured Company. See the full profile at https://b2idigital.com/exozymes-1. As Michael Heltzen, CEO of eXoZymes, explains in the interview, GLP-1 drugs reduce appetite while NCT supports metabolism in a different way. He notes that NCT has been part of the human diet for a long time, although meaningful do
FacebookB2i Digital
1 views3 days ago
Pharmaceutical Development and Technology Articles
Why Quality Control department important in the pharmaceutical industry? #pharma#qualitycontrol
0:27
Why Quality Control department important in the pharmaceutical industry? #pharma#qualitycontrol
YouTubeThe Pharma Show by seji
5.5K viewsOct 30, 2023
Bio-Pharmaceutical company AstraZeneca to invest $50 billion in US for drug R&D, says Trump
1:31
Bio-Pharmaceutical company AstraZeneca to invest $50 billion in US for drug R&D, says Trump
YouTubeANI News
6.3K views1 month ago
Trump reaches deal with AstraZeneca to lower U.S. drug prices
0:24
Trump reaches deal with AstraZeneca to lower U.S. drug prices
YouTubeCNBC Television
7.1K views1 month ago